Fatigue
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Fatigue is a highly competitive landscape with 103 programs across 44 companies. The most active players are Alnylam Pharmaceuticals, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 33 therapies are approved with 13 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Alnylam Pharmaceuticals
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1 program
Neurim Pharmaceuticals Ltd.
1 program
Roche
1 program
AVM Biotechnology Inc
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
98%
Small molecule
110 of 112 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 112 classified programs, each share of the total. Modality classified for 99% of 117 pipeline programs.
Analysis
Trial Status
148
clinical trials
Clinical Trials
Trial Activity
148 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)